Executive Summary
This intelligence brief reveals a severe and concentrated wave of corporate distress across US-listed companies, with 8 out of 10 filings detailing active delisting threats or non-compliance with exchange listing standards. The dominant theme is a liquidity and market capitalization crisis, with companies like Silexion, SANUWAVE, Dyadic, and Fusemachines all failing to meet minimum bid price or market value thresholds.
The period-over-period data, though limited in this set, points to sustained net losses and equity erosion, as seen in Southland Holdings' $248.2M stockholders' deficit and Calidi Biotherapeutics' sub-$4M equity base. A notable divergence is the voluntary, strategic transfer of Lumen Technologies to Nasdaq, which stands in stark contrast to the involuntary delistings. Insider trading activity is absent across these filings, suggesting a lack of management conviction or an inability to signal confidence. The most critical development is the immediate suspension of SilverBox Corp IV's NYSE trading, forcing it to the OTC market, while the October 2026 compliance plan deadlines for Netcapital, Southland, and Calidi create a high-stakes catalyst calendar. The market implication is clear: investors face a binary risk of total equity loss through forced delistings, with limited recovery prospects for common shareholders.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K
Tracking the trend? Catch up on the prior US Corporate Distress Financial Stress SEC Filings digest from September 24, 2026.
Investment Signals (10)
- Lumen Technologies ↓ (BULLISH)▲
Voluntary transfer to Nasdaq on Oct 6, 2026, signals strategic alignment with AI enterprise focus, avoiding stigma of involuntary delisting. CEO Kate Johnson's framing suggests proactive management.
-
Potential distribution of ~470M warrants (exercise price $12-$16) tied to WBD merger creates a high-leverage catalyst; if merger closes, warrant overhang could depress stock but offers long-term optionality. [BULLISH/BEARISH]
-
Immediate delisting and OTC transfer creates a distressed asset play; if underlying business has value, OTC trading may allow for a low-entry accumulation before potential relisting. [BULLISH (for deep-value investors)]
-
180-day compliance window (until Mar 22, 2027) provides time for a potential turnaround or strategic transaction; management is evaluating options including transfer to Nasdaq Capital Market. [BULLISH (if turnaround executed)]
- Dyadic International ↓ (BULLISH)▲
Company is actively considering a reverse stock split to regain bid price compliance, a concrete action plan that could restore listing status if executed before Mar 24, 2027.
- Netcapital Inc ↓ (BEARISH)▲
Delinquent filings (10-K and 10-Q) suggest operational disarray, but the Oct 23 compliance plan deadline creates a binary catalyst; if plan is accepted, exception until Feb 9, 2027 provides breathing room.
- Fusemachines Inc ↓ (BEARISH)▲
Failed to regain compliance after initial 180-day notice (Mar 27, 2026), indicating a sustained inability to meet MVLS standards; delisting appears inevitable despite planned hearing request.
- Southland Holdings ↓ (BEARISH)▲
Three consecutive years of net losses and a $248.2M stockholders' deficit signal deep structural insolvency; the 18-month cure period (until Mar 23, 2028) is unusually long, suggesting NYSE expects a restructuring or sale.
- Calidi Biotherapeutics ↓ (BEARISH)▲
Stockholders' equity of only $3.1M against a $4.0M minimum, with net losses in 3 of last 4 years; the '.BC' noncompliance indicator will deter new buyers and pressure the stock further.
- Silexion Therapeutics ↓ (BEARISH)▲
Bid price below $1.00 for 30 consecutive days triggers delisting review; as an 'emerging growth company', it may have limited options to raise capital without diluting shareholders.
Risk Flags (9)
- SilverBox Corp IV/Immediate Delisting↓ [HIGH RISK]▼
Trading suspended on NYSE as of Sep 25, 2026; moves to OTC on Sep 28. No cure period, no compliance plan—immediate loss of exchange liquidity and visibility.
- Southland Holdings/Structural Insolvency↓ [HIGH RISK]▼
Stockholders' deficit of $248.2M and net losses in three consecutive fiscal years; even with an 18-month cure period, the deficit magnitude makes compliance nearly impossible without a major capital infusion.
- Fusemachines Inc/Repeat Failure↓ [HIGH RISK]▼
Received initial non-compliance notice on Mar 27, 2026, and failed to regain compliance within 180 days; delisting notice now issued, with only a hearing request as a last resort.
- Netcapital Inc/Regulatory Disarray↓ [HIGH RISK]▼
Delinquent on both annual (10-K) and quarterly (10-Q) filings, indicating severe internal control or financial reporting failures; compliance plan due Oct 23 is a high bar.
- Calidi Biotherapeutics/Equity Erosion↓ [HIGH RISK]▼
Stockholders' equity of $3.1M is 22.5% below the $4.0M minimum; net losses in 3 of 4 recent years suggest ongoing cash burn with no path to profitability.
- Silexion Therapeutics/Bid Price Deficiency↓ [MEDIUM RISK]▼
Ordinary share price below $1.00 for 30 consecutive days; as an Israeli-based emerging growth company, it may face additional hurdles in raising capital or communicating with US investors.
- SANUWAVE Health/MVLS Deficiency↓ [MEDIUM RISK]▼
Market value below $50M for 30 consecutive days; while a 180-day cure exists, the company's small size and negative sentiment make a quick recovery unlikely without a catalyst.
- Dyadic International/Dual Deficiency↓ [MEDIUM RISK]▼
Failing both bid price (<$1.00) and MVLS (<$35M) simultaneously; reverse stock split may fix bid price but could further reduce market cap if not accompanied by value creation.
- Paramount Skydance Corp/Merger Uncertainty↓ [MEDIUM RISK]▼
Warrant distribution contingent on WBD merger closing; no assurance on timing or completion creates binary risk—if merger fails, warrants vanish and stock may face pressure.
Opportunities (9)
- SilverBox Corp IV/OTC Accumulation↓ (OPPORTUNITY)◆
Stock moving to OTC on Sep 28 may trade at deep discounts; for investors with high risk tolerance, accumulating shares at distressed prices could yield outsized returns if company relists or is acquired.
- Lumen Technologies/Nasdaq Relisting↓ (OPPORTUNITY)◆
Transfer to Nasdaq on Oct 6 aligns with AI enterprise narrative; potential for multiple expansion as new investors (AI-focused funds) discover the stock on a new exchange.
- Paramount Skydance Corp/Warrant Catalyst↓ (OPPORTUNITY)◆
If WBD merger closes, ~470M warrants with exercise price $12-$16 will be distributed; early positioning before the Oct 5 record date could capture value from the optionality.
- Dyadic International/Reverse Split Catalyst↓ (OPPORTUNITY)◆
Company is actively considering a reverse stock split; if executed before Mar 24, 2027, it could restore bid price compliance and trigger a re-rating by algorithms and investors.
- SANUWAVE Health/Strategic Transfer Option↓ (OPPORTUNITY)◆
Management is evaluating transfer to Nasdaq Capital Market; if successful, it would provide a lower bar for continued listing, potentially stabilizing the stock.
- Southland Holdings/Restructuring Play↓ (OPPORTUNITY)◆
The 18-month cure period (until Mar 23, 2028) is unusually long; a distressed debt or equity investor could negotiate a restructuring that brings in new capital and fixes the stockholders' deficit.
- Calidi Biotherapeutics/Compliance Plan Window↓ (OPPORTUNITY)◆
The Oct 21 deadline for a compliance plan creates a near-term catalyst; if a credible plan (e.g., capital raise, merger) is submitted, the stock could see a temporary reprieve and price bounce.
- Netcapital Inc/Exception Window↓ (OPPORTUNITY)◆
If compliance plan is accepted by Oct 23, the company gets until Feb 9, 2027 to file; this creates a 4.5-month window for a potential white-knight investor or auditor to resolve filings.
- Fusemachines Inc/Hearing Arbitrage↓ (OPPORTUNITY)◆
The company plans to request a hearing before the Nasdaq Hearings Panel; if the panel grants a stay, it could provide a short window for a last-minute deal or capital raise.
Sector Themes (6)
- Delisting Wave Across Small-Cap Biotech and Tech◆
5 of 10 filings (Silexion, SANUWAVE, Dyadic, Fusemachines, Calidi) are in biotech/healthcare or emerging tech, all failing market cap or bid price standards. This suggests a sector-wide liquidity crunch as growth-stage companies struggle to maintain valuations post-2021 peak.
- NYSE vs Nasdaq Delisting Standards◆
NYSE (SilverBox, Southland, Calidi) enforces stricter equity and market cap thresholds ($40M market cap, $4M equity) while Nasdaq (Silexion, SANUWAVE, Dyadic, Fusemachines) focuses on bid price ($1.00) and MVLS ($35M-$50M). Investors should monitor which exchange their holdings are on to gauge risk.
- Compliance Plan Deadlines as Binary Catalysts◆
4 companies (Netcapital, Southland, Calidi, SANUWAVE) have near-term compliance plan deadlines (Oct 21-23, 2026). These create binary outcomes: either a credible plan is submitted (temporary reprieve) or delisting proceedings begin. The next 30 days are critical.
- Voluntary Transfer vs Involuntary Delisting◆
Lumen Technologies' voluntary transfer to Nasdaq (Oct 6) contrasts sharply with the 7 involuntary delisting threats. This bifurcation shows that healthy companies are proactively choosing exchanges, while distressed companies are being forced out, widening the quality gap between listed and delisted names.
- Absence of Insider Activity Signals Management Flight◆
Across all 10 filings, there is zero insider trading activity reported. In a distressed context, this is a bearish signal—management is neither buying to show confidence nor selling to exit, suggesting paralysis or lack of conviction in the company's future.
- Capital Allocation Vacuum◆
No company reported dividends, buybacks, or capital returns. This is consistent with distress: all available cash is being hoarded or burned, with zero shareholder returns. The absence of any capital allocation is itself a signal of financial strain.
Watch List (8)
-
Oct 23, 2026 deadline to submit plan; if accepted, exception until Feb 9, 2027. Watch for filing of delinquent 10-K and 10-Q.
-
Oct 21, 2026 deadline to submit plan; if accepted, cure period until Mar 21, 2028. Watch for capital raise or merger announcement.
-
Oct 23, 2026 deadline to submit plan; 18-month cure period until Mar 23, 2028. Watch for restructuring or equity infusion news.
-
Oct 5, 2026 record date for warrant distribution; contingent on WBD merger closing. Watch for merger progress and warrant terms.
-
Oct 6, 2026 listing on Nasdaq. Watch for volume and price action as stock transitions exchanges.
-
Sep 28, 2026 OTC trading begins. Watch for price discovery and any appeal to NYSE committee.
-
Mar 22, 2027 deadline to regain MVLS of $50M. Watch for strategic transfer to Nasdaq Capital Market or capital raise.
-
Mar 24, 2027 deadline for bid price and MVLS compliance. Watch for reverse stock split announcement or implementation.
Filing Analyses
(10)
25-09-2026
Silexion Therapeutics Corp (SLXN/SLXNW) disclosed on September 25, 2026 that it received a Nasdaq Staff letter notifying the company that its ordinary share closing bid price has been below the $1.00 minimum for 30 consecutive business days, triggering a potential delisting review under Nasdaq Listing Rule 5550(a)(2). The Nasdaq hearings panel will consider the bid price deficiency in its decision on whether to allow Silexion to remain listed on the Nasdaq Capital Market. The letter has no immediate effect on trading of the ordinary shares (SLXN) or warrants (SLXNW), which continue to trade as usual pending the panel's decision.
- · The company is classified as an 'emerging growth company' under SEC Rule 405 and Rule 12b-2.
- · The company's principal executive offices are located in Ramat-Gan, Israel.
- · The company has not elected to use the extended transition period for complying with new or revised financial accounting standards.
- · The filing includes standard forward-looking statement disclaimers and risk factor references to the company's 2025 Form 10-K.
25-09-2026
SANUWAVE Health, Inc. received a Nasdaq notice on September 23, 2026, for failing to maintain the minimum Market Value of Listed Securities (MVLS) of $50,000,000, as its MVLS remained below this threshold for 30 consecutive business days. The company has a 180-day compliance period until March 22, 2027, to regain compliance, with no immediate impact on its Nasdaq Global Market listing. Management is evaluating options, including a potential transfer to the Nasdaq Capital Market, but there is no assurance of maintaining the listing.
- · Compliance deadline is March 22, 2027, to regain MVLS of at least $50,000,000 for 10 consecutive business days.
- · If compliance is not regained, the company will receive written notification that its securities are subject to delisting.
- · The company may consider transferring its listing to The Nasdaq Capital Market if it meets the applicable continued listing requirements.
25-09-2026
Paramount Skydance Corp (PSKY) announced it will voluntarily transfer its stock listing from Nasdaq to the NYSE effective October 6, 2026, and set a record date of October 5, 2026 for a distribution of warrants to purchase Class B common stock. The warrant distribution—expected to be approximately 470 million warrants—is contingent on the closing of the pending Warner Bros. Discovery merger, which remains uncertain with no assurance on timing or completion. The warrants will have an exercise price between $12.00 and $16.02 per share, expire 10 years after issuance, and may be redeemed early if the stock price hits $30.00 for 20 out of 30 consecutive trading days after the third anniversary, while certain holders and plans are excluded or receive shares instead.
- · The warrant distribution excludes Restricted Holders (Lawrence J. Ellison, David F. Ellison, Gerald J. Cardinale, the Lawrence J. Ellison Revocable Trust, and RedBird Capital Partners Fund IV) and their affiliates, as well as the Paramount Global 401(k) Plan and Paramount Global Master Trust (which will receive shares instead of warrants).
- · The warrants will trade separately on the NYSE if approved.
- · The Company may cancel or postpone the record date and/or issue date at its discretion if the WBD Merger does not close as expected.
25-09-2026
Netcapital Inc. received a Nasdaq notice on September 21, 2026, for failure to comply with Listing Rule 5250(c)(1) due to delinquent filing of its Form 10-K (fiscal year ended April 30, 2026) and Form 10-Q (quarter ended July 31, 2026). The company has until October 23, 2026, to submit a compliance plan, and if accepted, may receive an exception until February 9, 2027. While the notice has no immediate effect on trading, the company faces potential delisting risk if it fails to regain compliance.
- · The company remains delinquent in filing its Form 10-K for the fiscal year ended April 30, 2026, and its Form 10-Q for the quarter ended July 31, 2026.
- · The company has until October 23, 2026, to submit a plan to regain compliance with Nasdaq.
- · If Nasdaq accepts the plan, the company may receive an exception of up to 180 calendar days, until February 9, 2027, to regain compliance.
- · The company's common stock will continue to trade on The Nasdaq Capital Market under the symbol 'NCPL' pending compliance.
- · The company issued a press release on September 25, 2026, announcing the receipt of the Notice, as required by Nasdaq Listing Rule 5810(b).
25-09-2026
Southland Holdings, Inc. received a delisting notice from NYSE American on September 23, 2026, for failing to meet continued listing standards due to a stockholders' deficit of $248.2 million and net losses in the last three fiscal years. The company must submit a compliance plan by October 23, 2026, and has until March 23, 2028, to regain compliance. While the stock and warrants continue trading for now, failure to submit or execute an acceptable plan will trigger delisting proceedings.
- · The company reported net losses in its last three fiscal years and is not eligible for any exemption under Section 1003(a) of the NYSE American Company Guide.
- · The compliance plan deadline is October 23, 2026, and the cure period extends to March 23, 2028.
- · If the plan is accepted but compliance is not achieved by March 23, 2028, or progress is insufficient, delisting proceedings will commence.
- · The company may appeal a staff delisting determination under Section 1010 and Part 12 of the Company Guide.
- · The notice does not affect business operations or SEC reporting obligations.
25-09-2026
On September 25, 2026, Dyadic International received a Nasdaq deficiency notice for failing to maintain the minimum bid price of $1.00 per share for 30 consecutive business days, as well as a separate notice for failing to maintain the minimum Market Value of Listed Securities (MVLS) of $35 million. The company has until March 24, 2027, to regain compliance with both requirements, though there is no immediate impact on its Nasdaq listing. The company plans to monitor its stock price and evaluate options, including a potential reverse stock split, to regain compliance.
- · Compliance Date for both bid price and MVLS deficiencies is March 24, 2027
- · Company may be eligible for an additional 180-day compliance period if it meets MVLS and other initial listing standards on the Compliance Date
- · If compliance is not regained, Nasdaq Staff will provide written notification that the common stock is subject to delisting
- · Company may appeal any delisting determination to a hearings panel, but there is no assurance of success
- · Company intends to actively monitor bid price and MVLS and evaluate options including a potential reverse stock split
25-09-2026
SilverBox Corp IV received a notice from NYSE Regulation on September 25, 2026, that it has fallen below the continued listing standard requiring a minimum average aggregate global market capitalization of $40,000,000 over 30 consecutive trading days, leading to delisting proceedings. Trading on the NYSE has been suspended, and the company's securities will begin trading on the OTC market on September 28, 2026. The company has the right to appeal the decision to a NYSE committee.
- · The delisting is based on Section 802.01B of the NYSE Listed Company Manual for failing to maintain a $40M average aggregate global market capitalization over 30 consecutive trading days.
- · Trading on the NYSE has been suspended as of the date of the notice (September 25, 2026).
- · OTC trading under the same ticker symbols begins September 28, 2026.
- · The company has the right to appeal the Staff's determination to a Committee of the Board of Directors of the NYSE.
25-09-2026
Fusemachines Inc. (FUSEW) received a Nasdaq delisting notice on September 24, 2026, for failing to maintain the minimum Market Value of Listed Securities (MVLS) of $50 million required for continued listing on the Nasdaq Global Market. The company had been given 180 days (until September 23, 2026) to regain compliance but failed to do so. Fusemachines plans to request a hearing before the Nasdaq Hearings Panel to stay the delisting, but there is no assurance the Panel will grant continued listing.
- · The company's common stock (FUSE) and warrants (FUSEW) are both traded on Nasdaq and subject to delisting.
- · The company is an emerging growth company and has not elected to use the extended transition period for complying with new accounting standards.
- · The initial non-compliance notice was received on March 27, 2026.
- · The company plans to request a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting action until the hearing and any granted extension expire.
25-09-2026
Calidi Biotherapeutics received a delisting notice from NYSE American on September 21, 2026, for failing to meet the minimum stockholders' equity requirement of $4.0 million, reporting only $3.1 million as of June 30, 2026, and net losses in three of the four most recent fiscal years. The company has until October 21, 2026, to submit a compliance plan and until March 21, 2028, to regain compliance, but faces delisting proceedings if the plan is not accepted or progress is insufficient. The notice does not immediately affect trading, but the stock will carry a '.BC' indicator of noncompliance.
- · The company has until October 21, 2026, to submit a compliance plan to NYSE American.
- · If the plan is accepted, the company must regain compliance by March 21, 2028, or face delisting.
- · The common stock will continue trading under symbol 'CLDI' but with a '.BC' indicator denoting noncompliance.
- · The company reported net losses in three of its four most recent fiscal years ended December 31, 2025.
- · The company is not currently eligible for any exemption from the stockholders' equity requirements.
25-09-2026
Lumen Technologies voluntarily notified the NYSE of its intention to delist its common stock and certain Qwest Corporation notes, with the listing transferring to Nasdaq. The transfer is expected to be effective on October 6, 2026, with the same trading symbols maintained. CEO Kate Johnson framed the move as aligning with Lumen's transformation into an enterprise networking company for AI.
- · The delisting from NYSE is expected at the close of trading on October 5, 2026, and listing on Nasdaq at the opening on October 6, 2026.
- · The Securities include Common Stock (LUMN), Preferred Stock Purchase Rights, and Qwest Corporation's 6.500% Notes due 2051 (CTGG) and 6.750% Notes due 2052 (CTHH).
- · Registration of transfer was approved by the boards of both Lumen and Qwest Corporation.
Get daily alerts with 10 investment signals, 9 risk alerts, 9 opportunities and full AI analysis of all 10 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Corporate Distress Financial Stress SEC Filings
September 23, 2026
US Corporate Distress Financial Stress SEC Filings — September 23, 2026
September 22, 2026
US Corporate Distress Financial Stress SEC Filings — September 22, 2026
September 21, 2026
US Corporate Distress Financial Stress SEC Filings — September 21, 2026
September 18, 2026
US Corporate Distress Financial Stress SEC Filings — September 18, 2026
🇺🇸 More from United States
View all →September 28, 2026
US Pre-Market SEC Filings Roundup — September 28, 2026
US Pre-Market SEC Filings Roundup
September 28, 2026
US Merger & Acquisition SEC Filings — September 28, 2026
US Merger & Acquisition SEC Filings
September 28, 2026
USA Insider Trading Pulse — September 28, 2026
USA Insider Trading Pulse
September 28, 2026
US Corporate Board Director Changes SEC Filings — September 28, 2026
US Corporate Board Director Changes SEC Filings